liver disorders

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc’s (NASDAQ: ALBO) Bylvay (odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)...

Genome editing company, LogicBio Therapeutics, plans to begin trading on the Nasdaq under the ticker symbol “LOGC.” The Company LogicBio develops medicines to treat rare diseases with the ;GeneRide platform. This technology is designed to precisely integrate corrective genes into a...